JP Morgan Chase
REGN icon

JP Morgan Chase’s Regeneron Pharmaceuticals REGN Stock Holding History

JP Morgan Chase’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38B Sell
3,774,199
-537,607
-12% -$366M 0.13% 150
2026
Q1 		$3.23B Buy
4,311,806
+371,646
+9% +$285M 0.21% 106
2025
Q4 		$3.04B Sell
3,940,160
-132,166
-3% -$89.8M 0.19% 113
2025
Q3 		$2.29B Buy
4,072,326
+132,708
+3% +$75M 0.14% 151
2025
Q2 		$2.07B Sell
3,939,618
-1,718,579
-30% -$959M 0.14% 151
2025
Q1 		$3.59B Sell
5,658,197
-1,401,174
-20% -$964M 0.26% 83
2024
Q4 		$5.03B Sell
7,059,371
-430,129
-6% -$361M 0.37% 47
2024
Q3 		$7.87B Sell
7,489,500
-787,815
-10% -$877M 0.6% 21
2024
Q2 		$8.7B Buy
8,277,315
+550,141
+7% +$533M 0.71% 18
2024
Q1 		$7.44B Buy
7,727,174
+500,405
+7% +$476M 0.63% 20
2023
Q4 		$6.35B Sell
7,226,769
-162,385
-2% -$134M 0.61% 19
2023
Q3 		$6.08B Buy
7,389,154
+845,167
+13% +$664M 0.67% 21
2023
Q2 		$4.7B Buy
6,543,987
+199,836
+3% +$154M 0.51% 28
2023
Q1 		$5.21B Buy
6,344,151
+234,606
+4% +$177M 0.64% 23
2022
Q4 		$4.41B Buy
6,109,545
+403,676
+7% +$298M 0.58% 25
2022
Q3 		$3.93B Buy
5,705,869
+27,437
+0.5% +$17.3M 0.56% 26
2022
Q2 		$3.36B Buy
5,678,432
+713,465
+14% +$464M 0.47% 37
2022
Q1 		$3.47B Buy
4,964,967
+373,438
+8% +$236M 0.42% 46
2021
Q4 		$2.9B Buy
4,591,529
+489,084
+12% +$301M 0.33% 63
2021
Q3 		$2.48B Buy
4,102,445
+314,052
+8% +$195M 0.31% 70
2021
Q2 		$2.12B Buy
3,788,393
+752,738
+25% +$381M 0.25% 86
2021
Q1 		$1.44B Buy
3,035,655
+721,261
+31% +$351M 0.19% 125
2020
Q4 		$1.12B Buy
2,314,394
+391,040
+20% +$211M 0.16% 143
2020
Q3 		$1.1B Buy
1,923,354
+125,884
+7% +$76.3M 0.19% 120
2020
Q2 		$1.12B Buy
1,797,470
+568,057
+46% +$322M 0.22% 109
2020
Q1 		$600M Buy
1,229,413
+9,526
+0.8% +$3.93M 0.14% 160
2019
Q4 		$458M Buy
1,219,887
+764,436
+168% +$257M 0.09% 251
2019
Q3 		$126M Sell
455,451
-96,471
-17% -$28.5M 0.03% 585
2019
Q2 		$171M Sell
551,922
-743,350
-57% -$247M 0.03% 497
2019
Q1 		$532M Buy
1,295,272
+1,036,855
+401% +$427M 0.11% 207
2018
Q4 		$96.5M Buy
258,417
+28,807
+13% +$10.5M 0.02% 632
2018
Q3 		$92.8M Buy
229,610
+78,013
+51% +$29.7M 0.02% 730
2018
Q2 		$52.3M Sell
151,597
-11,631
-7% -$3.64M 0.01% 946
2018
Q1 		$56.2M Sell
163,228
-52,160
-24% -$18.1M 0.01% 876
2017
Q4 		$81M Sell
215,388
-129,030
-37% -$52.3M 0.02% 751
2017
Q3 		$150M Buy
344,418
+119,508
+53% +$56.9M 0.03% 490
2017
Q2 		$110M Sell
224,910
-53,739
-19% -$23.5M 0.03% 585
2017
Q1 		$108M Sell
278,649
-58,522
-17% -$21.7M 0.02% 605
2016
Q4 		$124M Sell
337,171
-697,019
-67% -$265M 0.03% 514
2016
Q3 		$417M Sell
1,034,190
-401,961
-28% -$161M 0.1% 221
2016
Q2 		$502M Sell
1,436,151
-27,541
-2% -$10.6M 0.13% 186
2016
Q1 		$528M Sell
1,463,692
-1,189,931
-45% -$490M 0.14% 174
2015
Q4 		$1.44B Buy
2,653,623
+114,453
+5% +$62M 0.36% 50
2015
Q3 		$1.18B Buy
2,539,170
+103,791
+4% +$55.7M 0.32% 61
2015
Q2 		$1.24B Buy
2,435,379
+160,171
+7% +$78.2M 0.29% 63
2015
Q1 		$1.03B Buy
2,275,208
+512,962
+29% +$217M 0.23% 89
2014
Q4 		$723M Buy
1,762,246
+218,398
+14% +$85.9M 0.17% 132
2014
Q3 		$557M Sell
1,543,848
-136,585
-8% -$45.8M 0.13% 170
2014
Q2 		$475M Buy
1,680,433
+104,139
+7% +$30.9M 0.12% 191
2014
Q1 		$473M Sell
1,576,294
-274,063
-15% -$84.4M 0.13% 179
2013
Q4 		$509M Sell
1,850,357
-707,221
-28% -$203M 0.14% 161
2013
Q3 		$800M Sell
2,557,578
-331,959
-11% -$87.3M 0.24% 89
2013
Q2 		$650M Buy
+2,889,537
New +$673M 0.21% 103

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

JP Morgan Chase's REGN Position: Q2 2026 in Review

JP Morgan Chase reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $366M and leaving 3,774,199 shares worth $2.38B. The position accounts for 0.13% of the portfolio, ranked #150.

JP Morgan Chase first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.7B in Q2 2024. 1,067 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • JP Morgan Chase held 3,774,199 shares of Regeneron Pharmaceuticals worth $2.38B as of Q2 2026.
  • JP Morgan Chase sold 537,607 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $366M.
  • Regeneron Pharmaceuticals made up 0.13% of JP Morgan Chase's portfolio in Q2 2026, its #150 holding.
  • JP Morgan Chase first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Regeneron Pharmaceuticals position peaked at $8.7B in Q2 2024.
  • 1,067 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.